OPN1SW and acute lymphoblastic leukemia: The safety and efficacy of CAT CAR-T were subsequently investigated in the Phase II CARPALL study (NCT02443831) in which 14 R/R BCP-ALL patients were infused, 10 (71%) after post-HSCT relapse (25).